DensMedika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 198,927 | 235,195 | 276,034 | 266,144 | 320,122 | 185,898 | 133,572 | 109,744 |
| Profit before tax | 1,436 | 9,687 | 29,399 | 6,883 | 13,661 | 2,880 | -6,157 | 1,863 |
| Net profit | 1,204 | 6,924 | 24,107 | 5,378 | 11,266 | 2,074 | -6,157 | 1,774 |
| Equity | 48,993 | 55,917 | 80,024 | 85,402 | 96,668 | 98,742 | 92,585 | 94,359 |
| Liabilities | 132,703 | 121,406 | 130,644 | 132,982 | 163,464 | 107,361 | 89,095 | 76,590 |
| Non-current assets | 100,190 | 80,875 | 105,310 | 112,837 | 158,482 | 125,748 | 108,114 | 91,112 |
| Current assets | 81,506 | 96,448 | 105,358 | 105,547 | 101,650 | 80,355 | 73,566 | 79,837 |
| Total assets | 181,696 | 177,323 | 210,668 | 218,384 | 260,132 | 206,103 | 181,680 | 170,949 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 49,598 | 27,901 | 22,148 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -22.5% | +18.2% | +17.4% | -3.6% | +20.3% | -41.9% | -28.1% | -17.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.7% | 3.9% | 11.4% | 2.5% | 4.3% | 1.0% | -3.4% | 1.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 2.5% | 12.4% | 30.1% | 6.3% | 11.7% | 2.1% | -6.7% | 1.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.6% | 2.9% | 8.7% | 2.0% | 3.5% | 1.1% | -4.6% | 1.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 0.7% | 4.1% | 10.7% | 2.6% | 4.3% | 1.5% | -4.6% | 1.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.7 | 2.2 | 1.6 | 1.6 | 1.7 | 1.1 | 1.0 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 66,309 | 78,398 | 92,011 | 88,715 | 120,044 | 92,949 | 84,363 | 109,744 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
DensMedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-03 | 2026-05-11 | 0.18 |
| 2026-04-24 | 2026-04-29 | 0.18 |
| 2026-01-16 | 2026-01-20 | 116.99 |
| 2025-07-24 | 2025-08-11 | 0.51 |
| 2025-06-17 | 2025-07-01 | 116.99 |
| 2022-07-25 | 2022-08-15 | 3.92 |
| 2022-05-17 | 2022-05-22 | 934.21 |
| 2022-04-19 | 2022-04-21 | 934.21 |
DensMedika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-04-04 | 2025-04-04 | 125.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
DensMedika, UAB (code 302916183) is a private limited liability company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €109.7K, down from €133.6K in 2024 and €185.9K in 2023, showing a clear two-year contraction in sales. Despite the weaker top line, profitability returned in 2025 with net profit of €1.8K, compared with a net loss of €6.2K in 2024 and net profit of €2.1K in 2023. The 2025 profit margin was 1.6%, after -4.6% in 2024 and 1.1% in 2023. At the balance sheet level, total assets declined from €206.1K in 2023 to €170.9K in 2025, while equity remained relatively stable at €94.4K. Liabilities decreased to €76.6K from €107.4K in 2023. Key ratios for 2025 indicate moderate balance-sheet strength and limited returns: ROE was 1.9%, ROA 1.0%, debt-to-equity 0.81, and asset turnover 0.64x. Revenue per employee was €109.7K and profit per employee €1.8K in 2025.